Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is male with essential hypertension (high blood pressure)~* Participant is in good general health (with the exception of hypertension)~* Participant has a Body Mass Index (BMI) \<= 33 kg/m\^2 at the Screening visit~* Participant has a platelet count \>= 150,000 cu/mL at the Screening visit~* Participant has a positive AIx at the Screening visit~Exclusion Criteria:~* Participant has a history of stroke, chronic seizure, or major neurological disease~* Participant has a functional disability that can interfere with rising from a seated position to the standing position~* Participant has any history of a bleeding or clotting disorder~* Participant has a history of cancer~* Participant is unable to refrain from or anticipates the use of any prescription or non-prescription medication~* Participant consumes excessive amounts of alcohol or caffeinated beverages daily

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Panel A: MK-8266 BID, 1 mg/Placebo (Type: EXPERIMENTAL): MK-8266 1 mg (0.7 mg in the morning \[AM\] + 0.3 mg in the evening \[PM\]), or as matching placebo BID.
- Panel B: MK-8266 BID, 1.8 mg/Placebo (Type: EXPERIMENTAL): MK-8266 1.8 mg (1 mg in the AM + 0.8 mg in the PM), or as matching placebo BID.
- Panel C: MK-8266 TID, 1.8 mg/Placebo (Type: EXPERIMENTAL): MK-8266 TID, 1.8 mg (0.6 mg every 6 hours \[q6hr\]), or as matching placebo TID.
- Panel D: MK-8266 TID, 2.4 mg/Placebo (Type: EXPERIMENTAL): MK-8266 TID (Panel D), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel D was completed prior to initiation of Panel E.
- Panel E: MK-8266 TID, 2.4 mg/Placebo (Type: EXPERIMENTAL): MK-8266 TID (Panel E), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel E was initiated after completion of Panel D.

Based on this trial design, predict the completion outcome and termination type (if applicable).